Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome

Paul P. Dobesh, Katherine W. Phillips, Stuart T. Haines

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose. Considerations in selecting antithrombotic and antiplatelet therapy for patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), including patients undergoing percutaneous coronary intervention (PCI), are discussed, and case studies are used to illustrate. Summary. Patients with NSTE ACS for whom a conservative treatment strategy is selected should receive enoxaparin, fondaparinux, or unfractionated heparin (UFH) as anticoagulant therapy. In high-risk patients with NSTE ACS for whom an early invasive strategy is planned, enoxaparin and UFH are the agents with the highest level of evidence (evidence level A). Fondaparinux and bivalirudin can also be used, but they have a lower level of evidence (evidence level B). Since fondaparinux use in patients undergoing PCI has been associated with an increased risk for catheter-related thrombosis, the use of fondaparinux in PCI patients should be limited. The use of bivalirudin alone is as effective and has been associated with less bleeding than the use of UFH or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor in patients with NSTE ACS who undergo PCI. No benefit has been shown from adding bivalirudin to a GP IIb/IIIa inhibitor.The role of GP IIb/IIIa inhibitors in patients with NSTE ACS and elevated troponin levels who are undergoing PCI has been well established, even for patients receiving high-dose clopldogrel. Anti-platelet therapy with clopidogrel has been shown to reduce both acute and chronic events in patients with NSTE ACS, including patients undergoing PCI. A conventional 300-mg clopidogrel loading dose needs to be administered at least six hours before PCI to achieve an adequate antiplatelet effect. A 600-mg loading dose appears to shorten the time to achieve an adequate antiplatelet effect to about two hours. Conclusion. The choice of anticoagulant and antiplatelet agents, dose, and timing of administration can affect outcomes in patients with NSTE ACS.

Original languageEnglish (US)
Pages (from-to)S22-S28
JournalAmerican Journal of Health-System Pharmacy
Volume65
Issue number15 SUPPL. 7
DOIs
StatePublished - Aug 1 2008

Fingerprint

Acute Coronary Syndrome
Percutaneous Coronary Intervention
clopidogrel
Enoxaparin
Platelet Glycoprotein GPIIb-IIIa Complex
Therapeutics
Heparin
Anticoagulants
Troponin
Platelet Aggregation Inhibitors
Thrombosis
Blood Platelets
Catheters
Hemorrhage

Keywords

  • Acute coronary syndrome
  • Anticoagulants
  • Bivalirudin
  • Clopidogrel
  • Dosage
  • Drugs
  • Enoxaparin
  • Fondaparinux
  • Heparin
  • Platelet aggregation inhibitors
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome. / Dobesh, Paul P.; Phillips, Katherine W.; Haines, Stuart T.

In: American Journal of Health-System Pharmacy, Vol. 65, No. 15 SUPPL. 7, 01.08.2008, p. S22-S28.

Research output: Contribution to journalArticle

@article{7366c4b1dfb14176aea7d503dbac036b,
title = "Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome",
abstract = "Purpose. Considerations in selecting antithrombotic and antiplatelet therapy for patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), including patients undergoing percutaneous coronary intervention (PCI), are discussed, and case studies are used to illustrate. Summary. Patients with NSTE ACS for whom a conservative treatment strategy is selected should receive enoxaparin, fondaparinux, or unfractionated heparin (UFH) as anticoagulant therapy. In high-risk patients with NSTE ACS for whom an early invasive strategy is planned, enoxaparin and UFH are the agents with the highest level of evidence (evidence level A). Fondaparinux and bivalirudin can also be used, but they have a lower level of evidence (evidence level B). Since fondaparinux use in patients undergoing PCI has been associated with an increased risk for catheter-related thrombosis, the use of fondaparinux in PCI patients should be limited. The use of bivalirudin alone is as effective and has been associated with less bleeding than the use of UFH or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor in patients with NSTE ACS who undergo PCI. No benefit has been shown from adding bivalirudin to a GP IIb/IIIa inhibitor.The role of GP IIb/IIIa inhibitors in patients with NSTE ACS and elevated troponin levels who are undergoing PCI has been well established, even for patients receiving high-dose clopldogrel. Anti-platelet therapy with clopidogrel has been shown to reduce both acute and chronic events in patients with NSTE ACS, including patients undergoing PCI. A conventional 300-mg clopidogrel loading dose needs to be administered at least six hours before PCI to achieve an adequate antiplatelet effect. A 600-mg loading dose appears to shorten the time to achieve an adequate antiplatelet effect to about two hours. Conclusion. The choice of anticoagulant and antiplatelet agents, dose, and timing of administration can affect outcomes in patients with NSTE ACS.",
keywords = "Acute coronary syndrome, Anticoagulants, Bivalirudin, Clopidogrel, Dosage, Drugs, Enoxaparin, Fondaparinux, Heparin, Platelet aggregation inhibitors, Toxicity",
author = "Dobesh, {Paul P.} and Phillips, {Katherine W.} and Haines, {Stuart T.}",
year = "2008",
month = "8",
day = "1",
doi = "10.2146/ajhp080242",
language = "English (US)",
volume = "65",
pages = "S22--S28",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "15 SUPPL. 7",

}

TY - JOUR

T1 - Optimizing antithrombotic therapy in patients with non-ST-segment elevation acute coronary syndrome

AU - Dobesh, Paul P.

AU - Phillips, Katherine W.

AU - Haines, Stuart T.

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Purpose. Considerations in selecting antithrombotic and antiplatelet therapy for patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), including patients undergoing percutaneous coronary intervention (PCI), are discussed, and case studies are used to illustrate. Summary. Patients with NSTE ACS for whom a conservative treatment strategy is selected should receive enoxaparin, fondaparinux, or unfractionated heparin (UFH) as anticoagulant therapy. In high-risk patients with NSTE ACS for whom an early invasive strategy is planned, enoxaparin and UFH are the agents with the highest level of evidence (evidence level A). Fondaparinux and bivalirudin can also be used, but they have a lower level of evidence (evidence level B). Since fondaparinux use in patients undergoing PCI has been associated with an increased risk for catheter-related thrombosis, the use of fondaparinux in PCI patients should be limited. The use of bivalirudin alone is as effective and has been associated with less bleeding than the use of UFH or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor in patients with NSTE ACS who undergo PCI. No benefit has been shown from adding bivalirudin to a GP IIb/IIIa inhibitor.The role of GP IIb/IIIa inhibitors in patients with NSTE ACS and elevated troponin levels who are undergoing PCI has been well established, even for patients receiving high-dose clopldogrel. Anti-platelet therapy with clopidogrel has been shown to reduce both acute and chronic events in patients with NSTE ACS, including patients undergoing PCI. A conventional 300-mg clopidogrel loading dose needs to be administered at least six hours before PCI to achieve an adequate antiplatelet effect. A 600-mg loading dose appears to shorten the time to achieve an adequate antiplatelet effect to about two hours. Conclusion. The choice of anticoagulant and antiplatelet agents, dose, and timing of administration can affect outcomes in patients with NSTE ACS.

AB - Purpose. Considerations in selecting antithrombotic and antiplatelet therapy for patients with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), including patients undergoing percutaneous coronary intervention (PCI), are discussed, and case studies are used to illustrate. Summary. Patients with NSTE ACS for whom a conservative treatment strategy is selected should receive enoxaparin, fondaparinux, or unfractionated heparin (UFH) as anticoagulant therapy. In high-risk patients with NSTE ACS for whom an early invasive strategy is planned, enoxaparin and UFH are the agents with the highest level of evidence (evidence level A). Fondaparinux and bivalirudin can also be used, but they have a lower level of evidence (evidence level B). Since fondaparinux use in patients undergoing PCI has been associated with an increased risk for catheter-related thrombosis, the use of fondaparinux in PCI patients should be limited. The use of bivalirudin alone is as effective and has been associated with less bleeding than the use of UFH or enoxaparin plus a glycoprotein (GP) IIb/IIIa inhibitor in patients with NSTE ACS who undergo PCI. No benefit has been shown from adding bivalirudin to a GP IIb/IIIa inhibitor.The role of GP IIb/IIIa inhibitors in patients with NSTE ACS and elevated troponin levels who are undergoing PCI has been well established, even for patients receiving high-dose clopldogrel. Anti-platelet therapy with clopidogrel has been shown to reduce both acute and chronic events in patients with NSTE ACS, including patients undergoing PCI. A conventional 300-mg clopidogrel loading dose needs to be administered at least six hours before PCI to achieve an adequate antiplatelet effect. A 600-mg loading dose appears to shorten the time to achieve an adequate antiplatelet effect to about two hours. Conclusion. The choice of anticoagulant and antiplatelet agents, dose, and timing of administration can affect outcomes in patients with NSTE ACS.

KW - Acute coronary syndrome

KW - Anticoagulants

KW - Bivalirudin

KW - Clopidogrel

KW - Dosage

KW - Drugs

KW - Enoxaparin

KW - Fondaparinux

KW - Heparin

KW - Platelet aggregation inhibitors

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=49549124264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549124264&partnerID=8YFLogxK

U2 - 10.2146/ajhp080242

DO - 10.2146/ajhp080242

M3 - Article

C2 - 18653821

AN - SCOPUS:49549124264

VL - 65

SP - S22-S28

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 15 SUPPL. 7

ER -